U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H44O12.8H2O
Molecular Weight 728.7747
Optical Activity UNSPECIFIED
Defined Stereocenters 15 / 15
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OUABAIN OCTAHYDRATE

SMILES

O.O.O.O.O.O.O.O.C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C6=CC(=O)OC6)[C@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=TYBARJRCFHUHSN-DMJRSANLSA-N
InChI=1S/C29H44O12.8H2O/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31;;;;;;;;/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3;8*1H2/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-;;;;;;;;/m0......../s1

HIDE SMILES / InChI

Molecular Formula C29H44O12
Molecular Weight 584.6525
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 15 / 15
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23761677 http://www.druginfosys.com/drug.aspx?drugcode=537&type=9

There is no available information about this compound

CNS Activity

Curator's Comment: SMALL doses of ouabain have powerful central nervous depressant effects. Ouabain directly stimulates the PNS center in the brain

Originator

Curator's Comment: Ouabain was discovered and so named in 1888 by Amaud

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P50993
Gene ID: 477.0
Gene Symbol: ATP1A2
Target Organism: Homo sapiens (Human)
41.0 nM [Ki]
Target ID: P13637
Gene ID: 478.0
Gene Symbol: ATP1A3
Target Organism: Homo sapiens (Human)
15.0 nM [Ki]
63.0 nM [IC50]
37.0 nM [IC50]
Target ID: P05023|||Q9UJ20
Gene ID: 476.0
Gene Symbol: ATP1A1
Target Organism: Homo sapiens (Human)
50.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Ouabain

Approved Use

Ouabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias.
Primary
Ouabain

Approved Use

Ouabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias.
Primary
Ouabain

Approved Use

Ouabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias.
PubMed

PubMed

TitleDatePubMed
Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
2010-07-01
Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain.
2010-06
Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain.
2010-05
The new targets of ouabain in retinal interneurons of Sprague-Dawley rats.
2010-04-05
DNA damage after intracerebroventricular injection of ouabain in rats.
2010-02-26
Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain.
2010-02
Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes.
2010-01-01
Upregulation of Na+ and Ca2+ transporters in arterial smooth muscle from ouabain-induced hypertensive rats.
2010-01
Effects of long-term ouabain treatment on blood pressure, sodium excretion, and renal dopamine D(1) receptor levels in rats.
2010-01
Extracellular signal regulated kinase 5 mediates signals triggered by the novel tumor promoter palytoxin.
2009-12-01
Animal model of mania induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain.
2009-12
Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells.
2009-11-01
The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models.
2009-09
Low-dose ouabain constricts small arteries from ouabain-hypertensive rats: implications for sustained elevation of vascular resistance.
2009-09
Intracellular potassium stabilizes human ether-à-go-go-related gene channels for export from endoplasmic reticulum.
2009-04
Activation of BKCa channels by nitric oxide prevents coronary artery endothelial dysfunction in ouabain-induced hypertensive rats.
2009-01
Chronic ouabain treatment induces vasa recta endothelial dysfunction in the rat.
2009-01
Response of sodium pump to ouabain challenge in human glioblastoma cells in culture.
2009
Ouabain treatment changes the role of endothelial factors in rat resistance arteries.
2008-12-14
Structural and functional characteristic of a model for deep-seated lacunar infarct in rats.
2008-10-15
The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.
2008-08
ACTH-induced hypertension is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit.
2008-07
Chronic ouabain treatment enhances cardiac myosin ATPase activity in rats.
2008-07
Proteomics investigation of protein expression changes in ouabain induced apoptosis in human umbilical vein endothelial cells.
2008-06-01
Chronic ouabain treatment increases the contribution of nitric oxide to endothelium-dependent relaxation.
2008-06
Hepatocyte growth factor increases uptake of estradiol 17beta-D-glucuronide and Oatp1 protein level in rat hepatocytes.
2008-02-02
Endogenous brain Na pumps, brain ouabain-like substance and the alpha2 isoform in salt-dependent hypertension.
2007-12
Involvement of endogenous ouabain-like compound in the cardiac hypertrophic process in vivo.
2007-03-13
Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells.
2007-02
Functional heterogeneity of the "transporter" of electrogenic ionic pump of the Lumbricus terrestris somatic myocyte membrane.
2006-12
[Ouabain-induced apoptosis of Jurkat cells correlates with activation of caspase-3 and regulation of Bcl-2 gene family].
2006-10
[Changes in renal sodium transport during hypertension development in ouabain-hypertensive rats].
2006-10
Ouabain-induced hypertension enhances left ventricular contractility in rats.
2006-09-13
[Contribution of endothelin and its receptors to ouabain-induced hypertension in rats].
2006-09
Central and peripheral renin-angiotensin systems in ouabain-induced hypertension.
2006-08
Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: role of Na+/K+ ATPase.
2006-07
Alterations in structure and mechanics of resistance arteries from ouabain-induced hypertensive rats.
2006-07
Visual behavior of adult goldfish with regenerating retina.
2006-02-12
Ouabain at pathological concentrations might induce damage in human vascular endothelial cells.
2006-02
[Comparative study of properties of Na+, K+-ATPase and Mg2+-ATPase of the myometrium plasma membrane].
2005-12-13
Sodium pump alpha2 subunits control myogenic tone and blood pressure in mice.
2005-11-15
[Comparative analysis of the cardiac glycosides action on the growth of the cardiac tissue explants].
2005-11
[Renal sodium handling in ouabain-hypertensive rats].
2005-08
Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats.
1992
Identification and characterization of a ouabain-like compound from human plasma.
1991-07-15
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
1991-01-01
Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.
1990-09
[Pharmacological studies of celiprolol: III. Effects of celiprolol on the cardiovascular system and renal function, and its antiarrhythmic effects].
1990-04
Association of in vivo and in vitro propranolol levels in canine Purkinje fibers with antiarrhythmic effects.
1977-07
The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.
1968-09
Patents

Sample Use Guides

0.004 mg/kg - IV, as Recommended Initial dose 24 mg 24 hourly PO, as Maintenance dose
Route of Administration: Other
Ouabain (0.1 uM-1.0 uM) inhibits the Na+ pump and increases stored Ca2+ in cultured rat astrocytes.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:21:33 GMT 2025
Edited
by admin
on Mon Mar 31 19:21:33 GMT 2025
Record UNII
1K0J875G48
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PUROSTROPHAN
Preferred Name English
OUABAIN OCTAHYDRATE
Common Name English
NSC-757425
Code English
STROPHOPERM
Brand Name English
CARD-20(22)-ENOLIDE, 3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-1,5,11,14,19-PENTAHYDROXY-, OCTAHYDRATE, (1.BETA.,3.BETA.,5.BETA.,11.ALPHA.)-
Common Name English
ACOCANTHERIN OCTAHYDRATE
Common Name English
STRODIVAL
Brand Name English
Code System Code Type Description
EPA CompTox
DTXSID7040730
Created by admin on Mon Mar 31 19:21:33 GMT 2025 , Edited by admin on Mon Mar 31 19:21:33 GMT 2025
PRIMARY
CHEBI
472805
Created by admin on Mon Mar 31 19:21:33 GMT 2025 , Edited by admin on Mon Mar 31 19:21:33 GMT 2025
PRIMARY
PUBCHEM
6364534
Created by admin on Mon Mar 31 19:21:33 GMT 2025 , Edited by admin on Mon Mar 31 19:21:33 GMT 2025
PRIMARY
CAS
11018-89-6
Created by admin on Mon Mar 31 19:21:33 GMT 2025 , Edited by admin on Mon Mar 31 19:21:33 GMT 2025
PRIMARY
FDA UNII
1K0J875G48
Created by admin on Mon Mar 31 19:21:33 GMT 2025 , Edited by admin on Mon Mar 31 19:21:33 GMT 2025
PRIMARY
NSC
757425
Created by admin on Mon Mar 31 19:21:33 GMT 2025 , Edited by admin on Mon Mar 31 19:21:33 GMT 2025
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE